New hope for young adults battling leukemia: testing a powerful drug combo
NCT ID NCT07227584
Summary
This study is testing a combination of chemotherapy and an immunotherapy drug (blinatumomab) to treat a type of blood cancer called acute lymphoblastic leukemia (ALL) in adolescents and young adults. The goal is to see if this specific treatment plan is safe and effective for this age group. About 67 people aged 18 to 50 with newly diagnosed, Philadelphia chromosome-negative ALL will receive the treatment and be followed for up to 10 years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.